Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sanddollar, you insist on reposting posts from Raging Bull. Why? Just read the rules of the board. However you made a good point with your post. Just say it with out the repost. This is not Raging Bull. Thank you, and have a wonderful day.
From todays SEC Filing...
ValiMed(TM) has transitioned from a beta-test product in to a full-scale
production product. Year-on-year revenues are up significantly in 2006, as
compared to the three and nine month periods of 2005. Management does not expect
the revenues from ValiMed(TM) to grow in a linear or predictable manner due to
the fact that ValiMed(TM) is a new product that has just been introduced into
the market. It is more likely that revenues will be "lumpy" over the next
several quarters; with some quarters up and some down. This will continue into
the foreseeable future until we have more fully developed our distribution and
sales channels and are better able to predict quarterly sales more precisely.
In order to increase sales, CDEX must receive additional investment funding to
implement its business plan, fund its international marketing and sales
initiatives, and provide working capital in order to purchase production
materials and parts inventories. If the company is unable to obtain the required
funding that it needs through debt or equity financing in the near-term, the
value potential of the ValiMed(TM) product portfolio over the next eight months
cannot be realized.
Illicit Drug Detector
---------------------
On August 29, 2006, CDEX entered into a contract with Missouri State Highway
Patrol (MSHP) for the Meth Gun Pilot Test Program. CDEX anticipates beginning
the Pilot Test Program in September 2006 and completing the test by the end of
2006. CDEX expects to have to refine the design of the Meth Gun based upon
inputs from MSHP, and expects the Meth Gun to evolve into an "Illicit Drug
Detector" that is capable of detecting more than just methamphetamine. Assuming
a successful pilot test program with MSHP, CDEX expects to begin production
start-up in early Q1 of 2007 with first production deliveries anticipated in Q2
of 2007.
The Meth Gun is transitioning from a marketing demonstrator prototype, to a
beta-test product with a bona-fide law enforcement agency in the Missouri State
Highway Patrol, acting as a committed beta-test partner for CDEX. CDEX
management anticipates that the "Illicit Drug Detector" could become a
significant product portfolio for the company over the next five (5) years. In
order for the company to take this product through a successful beta-test
program, revise its design, start up a production line, and introduce it into
the market by Q2 2007, CDEX must receive additional investment funding to
implement its business plan, successfully complete the pilot test program with
MSHP, establish a national and international reseller and distribution network,
and enter into production. This will require investment to fund the production
start up, marketing and sales initiatives, and provide working capital in order
to purchase production materials and parts inventories. If the company is unable
to obtain the required funding that it needs through debt or equity financing,
in the near term, the potential of the "Illicit Drug Detector" product portfolio
cannot be realized.
Explosive Trace and Counterfeit Medication Drug Detectors
---------------------------------------------------------
CDEX management has placed the further development of these two products on hold
pending receipt of additional equity or debt financing. CDEX does not have the
financial resources, at this time, to engage the additional human resources or
incur the additional expenses that would be required to bring these products to
market.
Intellectual Property
---------------------
CDEX has a portfolio of five non-provisional patent applications and one
provisional patent application. We have received notice from the U.S. Patent and
Trademark Office (USPTO) that three of the applications contain allowable
subject matter and we are awaiting their issuance. The remaining three patent
applications are pending.
OK Sanddollar, I just zapped the post you requested to be removed. I have in the past removed posts of others for calling people names. I will continue to do so. Have a wonderful day.
Calling people names. Innuendoes. Are all off topic. The topic is CDEX.
I think it's quite funny that not one of you protested when the former board moderator would even pull PR's about CDEX. Or anypost that disagreed with him.
The posters here have more freedom now than they did with him.
Calm down Sanddollar, it's only a message board.
CDEX is the topic! Please.
I have asked you to stop. Do you? No! My original post had no reference to RB. Is that clear? I pulled my own posts, yet you continue. It is obvious why I am pulling posts. Now can it all end? Someone I wish I didn't know from New Jersey would keep this arguement going. Could that be you?
The post 16796 is not an admission at all! I have been to kind to you and your friends. I will watch more closely now. Thank you for the wake up call!
Keep in mind, that I let you and others get away with the same thing a few times. Didn't I? I know you and your non shareholder friends only want the negative side posted. I felt compelled to post what a shareholder who attended the meeting saw with his own eyes.
Stop already, what is your problem? My original post that was emailed to me. Had no reference to RB at all. So keep on accusing me of things I haven't done and I will keep pulling your posts. OK?
I removed it. How is that? Are you happy now? After all we wouldn't want a non shareholder who has taken such a negative position on CDEX to be unhappy!
I had no idea it was a RB post, as it was emailed to me. It is that simple.
Look xeno, I have to read this board because I am the moderator. I find your posts, and your friends posts totally useless. Odd isn't it, that you all know each other? That you have all been posting for years about CDEX! It's almost as if you have a vested interest. Dontcha know? Kapesh?
See ya. A hockey game is coming on in the frozen North.
Stay on topic please. This is not a LOCH or a Pink Sheet message board.
Be safe, and have a Happy New Year.
Give us all a break. At least put negative fantasies in your opinion. All of you non shareholders. You know who you are.
Nice increase in the PPS wouldn't you say?
MSN ALERT CDEX is trading at 0.23, UP 21.053% 11/28/06
CDEX Inc. (OTCBB:CEXI) - Wednesday's shares increased 35.71% over open to $0.19.
The volume was at 320,119. The company announced that the US Patent and
Trademark Office (USPTO) has issued patent number 7,154,102 to CDEX Inc. The
patent relates to system and method for detection and identification of chemical
substances. The invention provides a system and method utilizing, among other
things, fluorescence spectroscopy in the ultra-violet portion of the
electromagnetic spectrum to determine chemical species and concentrations. The
basic measuring system includes optics, a spectrograph, a detector, and an
energy source ("head" components), along with a computer and control electronics
and power source capable of generating and detecting unique fluorescence
signatures for individual and unique mixtures of chemical substances including,
for example, prescribed and/or compounded medications, alcohol products, food
types, synthetic drugs, narcotics, perfumes, liquids, and the like.
CDEX Inc. is a technology development company with a current focus on developing
and marketing products using chemical detection and validation technologies. At
present, CDEX is devoting its resources to two distinct areas: (i)
identification of substances of concern (e.g., explosives and illegal drugs for
homeland security); and (ii) validation of substances for anti-counterfeiting,
brand protection and quality assurance (e.g., validation of prescription
medication and detection of counterfeit or sub-par products for brand
protection). ValiMed is one line of CDEX products for the healthcare market.
CDEX is headquartered in Rockville, Maryland with its research and development
laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and
www.valimed.com.
CDEX to Centralize Operations in Tucson, Arizona
ROCKVILLE, Md.-- December 27, 2006 --CDEX Inc. (OTCBB: CEXI) announced today that it is implementing its plan to centralize its administrative and corporate functions in Tucson, Arizona. The move is expected to begin in early 2007 and be concluded by the end of the first quarter. The move does not impact the Company's special shareholder meeting scheduled for January 9, 2007. Information regarding the transition will be posted on the Company's web site at www.cdex-inc.com.
"This move has been on our planning horizon for a number of years and we are pleased that we are able to implement it now," said Dr. BD Liaw, Chairman of the Board of Directors. "It will improve communications and increase the company's overall operational efficiency and effectiveness. Mr. Jim Griffin, the current President and CEO of CDEX, has indicated to the board that he will not relocate to Tucson as a matter of personal choice for him and his family. Mr. Griffin will step down as President and CEO effective December 28, 2006. The board wishes to express its thanks to Mr. Griffin for his leadership of the company and wishes him and his family the very best in their future endeavors," said Dr. Liaw.
Mr. Tim Shriver will act as the interim President and CEO until such time as a permanent President and CEO is recruited into the company. Mr. Malcolm Philips, past President and CEO, has agreed to become a special advisor in Tucson to the board and Mr. Shriver to assist with the transition and move.
"I was part of and fully support this decision by the board of directors," said Jim Griffin, President and CEO of CDEX Inc. "Consolidating the operations of the company in one location is in the best interests of CDEX. I will assist the Board and company during the upcoming transition period in any way possible."
"The technology upon which this company was founded had its roots in Tucson, Arizona, and I am pleased that we are now able to implement this move," said Tim Shriver, the new President and CEO. "We appreciate the foundation that Jim has laid for us and will be calling upon his help during this transition period."
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market; and (ii) identification of substances of concern (e.g., illegal drugs for law enforcement in the homeland security market) CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Double Good News from Cdex today.
1. The new patent.
2. Cdex is moving to where they always planned to be.
Early on the plan was to have incorporated in Tucson, at some point in the future. Hands on operation. They are not closing the doors, and I guess Mr. Griffin did not want to re-locate.
I am very happy with this move. I feel the company will be better off with everybody in Tucson. IMHO
U. S. Patent and Trademark Office Issues Patent to CDEX Inc.
Provides System and Methods for Detection and Identification of Chemical Substance
ROCKVILLE, Md., Dec 27, 2006 (BUSINESS WIRE) -- CDEX Inc. (CEXI : cdex inc cl a
News , chart, profile, more
Last: 0.15+0.01+3.57%
9:47am 12/27/2006
CEXI0.15, +0.01, +3.6%) announced today that the US Patent and Trademark Office (USPTO) has issued patent number 7,154,102 to CDEX Inc. The patent relates to system and method for detection and identification of chemical substances.
Patent Abstract
The invention provides a system and method utilizing, among other things, fluorescence spectroscopy in the ultra-violet portion of the electromagnetic spectrum to determine chemical species and concentrations. The basic measuring system includes optics, a spectrograph, a detector, and an energy source ("head" components), along with a computer and control electronics and power source capable of generating and detecting unique fluorescence signatures for individual and unique mixtures of chemical substances including, for example, prescribed and/or compounded medications, alcohol products, food types, synthetic drugs, narcotics, perfumes, liquids, and the like.
"The issuance of this patent is a major milestone achievement for CDEX and affirms both our core technology and our approaches to applying it to a system and method that can be used to detect and identify chemical substances across multiple applications and settings," said Jim Griffin, CEO of CDEX Inc. "It will strengthen our ValiMed product offering and allow us to create future value for the company by applying this patent to the development of life safety products for the healthcare, security, and brand protection markets."
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market; and (ii) identification of substances of concern (e.g., illegal drugs for law enforcement in the homeland security market) CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
SOURCE: CDEX Inc.
CDEX Inc. Jerry Blair, Vice President Marketing & Sales 301-881-0080 / jblair@cdex-inc.com Copyright Business Wire 2006
Valimed:Englewood, CO (PRWEB) December 21, 2006 -- The new Valimed™ Medication Validation System and related information is now available at http://publicrelationsnewsroom.com/_wsn/page15.html for media and professional access. ValiMed, distributed by Baxa Corporation, validates medications and concentrations; allowing users to detect counterfeit products for brand protection, provide quality assurance for compounded products, and detect narcotic loss. The ValiMed System ensures patient safety in real time, by verifying that medications are correctly compounded.
ValiMed features patent-pending technology that validates in seconds the strength of compounded doses of high risk medications prior to dispensing. Verification of compounding accuracy and sterilization is a requirement under USP 27-NF 22 Chapter 797, which regulates the compounding of sterile products. The ValiMed System can play a key role in demonstrating the safety of compounded sterile products (CSPs) under these requirements.
The updated version of the ValiMed System incorporates reports used to comply with USP 797 requirements. It also features a modified disposable, requiring a reduced sample volume for testing. "This next-generation ValiMed System addresses customer requests," notes Baxa Corporation Product Manager Mark Thrasher. "It's more robust and the smaller sample requirement more easily accommodates current pharmacy work flows."
Baxa, a long-time proponent of hospital pharmacy safety initiatives recently launched its state-of-the-art STAR (Skills Training, Academics and Resources) Center for pharmacy and cleanroom skills training. Baxa designed and built the STAR Center as a fully USP 797-compliant pharmacy cleanroom to provide professional education on pharmacy practice, cleanroom principles and compliance to regulatory requirements.
The STAR Center, the only dedicated facility of its kind in the world for hands-on cleanroom experience and training in environmental monitoring and aseptic technique, provides a unique opportunity for industry professionals to learn best practice from subject-matter expert trainers. More information is available at http://www.baxa.com/starcenter.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Key products include Rapid-Fill™ Automated Syringe Fillers, Exacta-Med® Oral Dispensers, MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, and Exacta-Mix™ and MicroMacro™ Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg and The Netherlands; and distribution partners worldwide. Further information is available at http://www.baxa.com.
About CDEX, Inc.
CDEX Inc. (OTCBB: CEXI), the manufacturer of the ValiMed System, is a technology development company focused on producing equipment that uses using chemical detection and validation technologies. CDEX technology is focused currently on two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance. CDEX is headquartered in Rockville, Maryland, with a primary research and development laboratory in Tucson, Arizona. For more information, visit http://www.cdex-inc.com and http://www.valimed.com
Paige, ask all you want. I enjoy the discussion.
SD, just how childish can you get? Sassy posted on Raging Bull, and you brought the fight over here.
Didn't I just ask the board about being civil?
Both posts were pulled by the time I got home. Go post on RB if you want to respond.
Tis' the season isn't it?
Sorry wrong again Crow. As per the conference call. JG stated this,
I will say that as of the last 10-Q we had forecasted our sales would be in the
range of $700 to $1 million. We fully expect to be on the upper end of that range with the filing of our 10-Q for the fourth quarter. We think we'll be in
the range of around $900,000 to $950,000, somewhere in that range, okay?
First of all I would like to wish all of you a very Merry of Christmas, Happy Holidyas, and a Happy New Year. With the spirit of the Christmas season upon us, please read the rest of this post.
Nastiness breeds more Nastiness. Sinicism breeds more Sinicism. Why do most of you attack the people you disagree with? When the subject is CDEX. If you would just post about the subject, the posts wouldn't shift into personal insults. Anybody checking this board out, would run after reading the nasty posts.
When I said that maybe a 100 people read this particular message board, I may have over estimated. The power of the message boards is a joke. That was in the past 10 years. It's history. One group may discourage some, and the other smaller group might encourage some. As for effecting the stock price, not from this message board. Maybe a few people bought or sold because of what they read here, but not many. IMHO.
Be civil please. Thanks, The Vike
The 8K filing from the Conference Call.
http://www.sec.gov/Archives/edgar/data/1173738/000121465906002377/0001214659-06-002377.txt
CDEX gets hit by the ASD lawsuit, and spends it's operating capitol on defending itself. CDEX settles the lawsuit. CDEX asks to authorize more shares to keep the doors open. That doesn't mean they use all of the authorized shares. Only what they need to sell, until some revenues come in. As long as the doors are open, we the shareholders have a chance. We have products with Valimed and the Meth-Gun in the market place.
Does this mean I am not concerned? Of course not. Do I wish that the company was further along? Of course I do. ASD cost us 7 month's, I think.
I wish that some of you would realize that this is a public message board. You are free to post almost anything. The key word almost. Please stop using real names. The subject of this board is CDEX.
I read a post referring to the power of the message boards. Are you serious? How many people do you actually think read this message board? Maybe 100 at most, and I doubt even that. Again I remind you, that I am not the only one who is allowed to pull posts.
Merry Christmas and Happy Holidays to all.
Please take it to the LOCH message board.
Thank you. I have provided the link below.
http://www.investorshub.com/boards/board.asp?board_id=190
Google Web Alert for: Valimed.
The ValiMed System by CDEX: Using New Technology to Validate ...
ValiMed technology will indicate a match, presuming there is ... The ValiMed drug detection device is a self-contained, 9 by 10 ...
http://publicrelationsnewsroom.com/db1/00055/publicrelationsnewsroom.com/_download
sandollar, What if people who didn't own this stock didn't but into shareholders lives? Who asked you and your naysayer friends opinion of anything? No less about how others invest. It is plain, none of your business. You are not a shareholder, and neither are most of the naysayers. Except one who owns two shares.
Logically speaking, it makes little sense to post negative for 6 years. Surely you all must have something better to do with your time. Enough said, I will not continue. Nor will I respond any more to this type of illogical behavior.
I have watched bigger buys than that go thru, and the MM's don't raise the 'ask', or the PPS. They are very quick to lower the PPS on one of phoney trades. Like 110 or 221 share trade. So I don't agree.
What if two market makers got together. At the request of some other company trying to put Cdex out of business. They buy a 100,000 shares, and sell them back and forth to each other. Dropping the PPS! The MM's never seem to raise the PPS on a buy, but they are very quick to lower the PPS. Aren't they?
I am voting a very big yes on my proxy vote.
Sandollar your last remarks to Paige where very uncalled for.
Knock off the personal attacks please.
Just as amazing that non shareholders have been posting negative for how many years. Is it 5, 6 or 7?
That doesn't mean the shares are all sold. Companies raise the amount of authorized shares all the time, big deal. They will sell a certain amount of shares to keep the company doors open. I would rather have the doors open. Remember it is only two for one dilution if they sell all the authorized shares. The nay sayers will rap badly on this. That is to be expected. The doors are not closing. We do have products. Don't panic! Don't let the nay sayers panic you!
CDEX will get the financing it needs, and not from a cut throat outfit.
IMHO
Did you ever think to add to your posts, that this is your not so humble opinion? This goes for the whole negative group, and you are a group.
The next quarter ends Oct. 31st. It appears that the {year ending quarterly} isn't due until the end of January. As they have a little more time to report it. Otherwise it would be 45 days after the quarter ends. Just a humble opinion. Last years 10K was filed on January 30th.
Why is it that some of the people that post here, have to make personal attacks? I will start to remove some of those posts.
Thank you for your cooperation.
FYI. I am not the only one removing posts.
By the way read the rules about bringing RB posts over here.
Knock it off already! Like a bad broken record. Can we stick to CDEX please.
Thank you for your support Matt.
Can you please leave the Raging Bull message board off of this board. Go post over on Raging Bull if you like it so much.
Again this is a CDEX board, not a Loch Harris board.
U.S. Federal District Court Dismisses ASD and CDEX Lawsuits with Prejudice
ROCKVILLE, Md., Oct 03, 2006 (BUSINESS WIRE) -- CDEX Inc. (OTCBB: CEXI)
announced today that the U.S. Federal District Court in Denver, Colorado has
reviewed and approved the Stipulation to Dismiss that was filed in the Court on
September 29, 2006 as part of a settlement agreement reached between ASD and
CDEX with regards to Civil Action No. 06-CV-426-RDB-CBS. Today, the Court
entered an Order of Dismissal with Prejudice and vacated all pending actions
before the Court.
This action by the Court brings to a final end the patent infringement lawsuit
that was filed by ASD against CDEX. It also brings to a final close CDEX's
counterclaims of invalidity and unenforceability that the company filed in
response to ASD's lawsuit.
"This case was settled in a manner that was fair and equitable to both parties,
while preserving the company's rights and protecting the interests of our
shareholders," said Jim Griffin, CDEX President and CEO.
About CDEX Inc.
CDEX Inc. is a chemical detection technology development company that uses its
expertise to develop and market life safety/public safety products for the
healthcare, homeland security, and brand protection markets. CDEX's ValiMed
Medication Validation System is used for quality assurance to ensure that
high-risk medications that are compounded in hospital pharmacies are the correct
medication, in the correct concentration, and correct diluent before they are
administered to patients. CDEX technology can be used in homeland security
market applications to identify suspicious substances such as trace amounts of
explosives, in liquid or solid form, and illegal drugs for law enforcement in
the homeland security market. CDEX is headquartered in Rockville, Maryland with
its research and development laboratory, engineering, and manufacturing
operations in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not
historical are essentially forward-looking. Many forward-looking statements can
be identified by the use of words such as "expects," "plans," "may,"
"anticipates," "believes," "should," "intends," "estimates," and other words of
similar meaning. These statements are subject to risks and uncertainties that
cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements.
Such risks are detailed from time-to-time in filings with the Securities and
Exchange Commission. There is no obligation to publicly update any
forward-looking statements.
SOURCE: CDEX, Inc.
U.S. Federal District Court Dismisses ASD and CDEX Lawsuits with Prejudice
ROCKVILLE, Md., Oct 03, 2006 (BUSINESS WIRE) -- CDEX Inc. (OTCBB: CEXI)
announced today that the U.S. Federal District Court in Denver, Colorado has
reviewed and approved the Stipulation to Dismiss that was filed in the Court on
September 29, 2006 as part of a settlement agreement reached between ASD and
CDEX with regards to Civil Action No. 06-CV-426-RDB-CBS. Today, the Court
entered an Order of Dismissal with Prejudice and vacated all pending actions
before the Court.
This action by the Court brings to a final end the patent infringement lawsuit
that was filed by ASD against CDEX. It also brings to a final close CDEX's
counterclaims of invalidity and unenforceability that the company filed in
response to ASD's lawsuit.
"This case was settled in a manner that was fair and equitable to both parties,
while preserving the company's rights and protecting the interests of our
shareholders," said Jim Griffin, CDEX President and CEO.
About CDEX Inc.
CDEX Inc. is a chemical detection technology development company that uses its
expertise to develop and market life safety/public safety products for the
healthcare, homeland security, and brand protection markets. CDEX's ValiMed
Medication Validation System is used for quality assurance to ensure that
high-risk medications that are compounded in hospital pharmacies are the correct
medication, in the correct concentration, and correct diluent before they are
administered to patients. CDEX technology can be used in homeland security
market applications to identify suspicious substances such as trace amounts of
explosives, in liquid or solid form, and illegal drugs for law enforcement in
the homeland security market. CDEX is headquartered in Rockville, Maryland with
its research and development laboratory, engineering, and manufacturing
operations in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not
historical are essentially forward-looking. Many forward-looking statements can
be identified by the use of words such as "expects," "plans," "may,"
"anticipates," "believes," "should," "intends," "estimates," and other words of
similar meaning. These statements are subject to risks and uncertainties that
cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements.
Such risks are detailed from time-to-time in filings with the Securities and
Exchange Commission. There is no obligation to publicly update any
forward-looking statements.
SOURCE: CDEX, Inc.